Literature DB >> 7572438

Scintigraphic detection of xenografted renal tumor by anti-renal cancer monoclonal antibody radiolabeled with technetium-99m.

K Mitsui1, T Taki, Y Miyagawa, Y Yamada, N Honda, H Fukatsu, K Yoshikawa, A Segawa.   

Abstract

Accumulation in the tumor of the RCS-1 monoclonal antibody, which recognizes the cell surface antigen of renal cancer cells was examined. The antibody purified by affinity chromatography (protein-A column) and gel fractionation was labeled with technetium-99m (99mTc) by a direct method. High labeling efficiency (> 98%) could be routinely obtained. However, the 99mTc labeling of the antibody did not reduce the reactivity of the RCS-1 antibody. The labeled antibody was injected into nude mice transplanted with human renal and gastric tumors, and the accumulation of the antibody in each tumor and various tissues was compared at 48 hours after injection. The highest accumulation of radiolabeled RCS-1 antibody was observed in the AM-RC-3 renal tumors; at 8.0% of the injected dose per gram and a tumor-to-blood ratio of 1.05, respectively. However, the radiolabeled RCS-1, did not show specific accumulation in the gastric tumor nor in any tissues tested. The xenografted tumor, AM-RC-3 was successfully visualized with the radiolabeled RCS-1 antibody by scintigraphy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7572438

Source DB:  PubMed          Journal:  Hinyokika Kiyo        ISSN: 0018-1994


  1 in total

1.  Radioimmunoscintigraphy of intracranial glioma xenograft with a technetium-99m-labeled mouse monoclonal antibody specifically recognizing type III mutant epidermal growth factor receptor.

Authors:  Syuntaro Takasu; Toshitada Takahashi; Sho Okamoto; Noboru Oriuchi; Norihisa Nakayashiki; Kenta Okamoto; Hideki Muramatsu; Takeshi Hayashi; Norimoto Nakahara; Masaaki Mizuno; Toshihiko Wakabayashi; Tetsuya Higuchi; Keigo Endo; Kenichi Kozaki; Osamu Miyaishi; Shinsuke Saga; Ryuzo Ueda; Jun Yoshida; Kazuhiro Yoshikawa
Journal:  J Neurooncol       Date:  2003-07       Impact factor: 4.130

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.